Vascular Endothelial Growth Factor Levels in Patients Undergoing Embryo Transfer

February 7, 2020 updated by: Ido Feferkorn, Carmel Medical Center
Assessing the relationship between the VEGF levels in blood and the IVF protocol

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The investigators are assessing the VEGF levels in the blood in IVF patients undergoing different protocols

Study Type

Observational

Enrollment (Anticipated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Female patients undergoing ovum pickup and embryo transfer as part of assited reproductive technologies

Description

Inclusion Criteria:

Patients undergoing IVF -

Exclusion Criteria:

  • Women with any malignancy
  • Patients request to be withdrawn

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
fresh
NO INTERVENTION
Other: NO intervention
NO INTERVENTION
Frozen embro transfer natural
NO INTERVENTION
Other: NO intervention
NO INTERVENTION
Frozen embro transfer hormonal
NO INTERVENTION
Other: NO intervention
NO INTERVENTION

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
vascular endothelial growth factor LEVELS
Time Frame: 5 days
levels of vascular endothelial growth factor in blood
5 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Carmel Medical Center

Investigators

  • Principal Investigator: Ido Feferkorn, MD, Carmel Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 1, 2020

Primary Completion (Anticipated)

March 1, 2021

Study Completion (Anticipated)

April 1, 2021

Study Registration Dates

First Submitted

February 6, 2020

First Submitted That Met QC Criteria

February 7, 2020

First Posted (Actual)

February 10, 2020

Study Record Updates

Last Update Posted (Actual)

February 10, 2020

Last Update Submitted That Met QC Criteria

February 7, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • CMC-19-0161-CTIL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Reproductive Techniques

Clinical Trials on NO intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe